Marc van der Waude, Marc van der Waude, Nov 01, 2009
The purpose of this contribution is to explore the status types that settlements and reverse payments could have under Article 81 EC. It seeks to identify the elements of the legal tests which could possibly be applied to assess the legality of such settlements and, in particular, those providing for a value transfer from the originator to the generic firm. This will be done as follows: Section 2 summarizes the main findings of the Final Report on settlement agreements; Section 3 makes an inventory of relatively old case law that dealt with comparable issues or those related to patent settlement agreements; and Section 4 makes an attempt to distill a legal test from the two previous sections for the assessment of patent settlement agreements between originator and generic firms under EC competition law.
Links to Full Content
Featured News
Spanish Minister Defends Record as Flood Crisis Casts Shadow on EU Role
Nov 22, 2024 by
CPI
UK Antitrust Regulator Signals Flexibility in Merger Reviews to Boost Economic Growth
Nov 21, 2024 by
CPI
US Supreme Court Declines to Hear Appeal in Google Antitrust Records Dispute
Nov 21, 2024 by
CPI
Matt Gaetz Withdraws from Consideration for US Attorney General Amid Controversy
Nov 21, 2024 by
CPI
Morocco Fines US Pharma Firm Viatris Over Merger Notification Breach
Nov 21, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI